The International Waldenstrom’s Macroglobulinemia Foundation (IWMF)
The International Waldenstrom’s Macroglobulinemia Foundation ((IWMF) is a patient-founded and patient-driven international nonprofit organization with a simple but compelling vision and mission.
OUR VISION: A world without WM (Waldenstrom’s macroglobulinemia)
OUR MISSION: Support and educate everyone affected by Waldenstrom’s macroglobulinemia (WM) while advancing the search for a cure. The IWMF is committed to creating a world without WM by finding a cure. Since 1999, the IWMF has invested over $20 million in WM research projects throughout the world. Thanks to this research WM patients have better treatment options that can lead to deeper, longer lasting remissions, and fewer side effects.
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
Resources & Support
Patient Worthy Posts on Waldenstrom Macroglobulinemia
Positive Results from Waldenstrom’s Macroglobulinemia Treatment Trial Means it will Continue
According to a recent article, the trial studying the success of CLR 131 to treat Waldenstrom’s macroglobulinemia has shown promising results, allowing it to continue.
Webinar: Waldenström’s Macroglobulinemia and Amyloidosis
On March 29, 2022, the International Waldenström’s Macroglobulinemia Foundation (IWMF) hosted a webinar titled “An Overview of Amyloidosis and WM with Dr. Morie Gertz.” The
Switzerland Approves BRUKINSA for Waldenstrom Macroglobulinemia
BRUKINSA (zanubrutinib) is a prescription medication which can be used to treat Waldenstrom macroglobulinemia (WM), mantle cell lymphoma, and marginal cell lymphoma. So far, the
Waldenström’s Macroglobulinemia: The Latest in Signs, Symptoms, and Diagnosis
According to an article from MedPage Today, Waldenström’s macroglobulinemia (WM) is a rare form of lymphoma. Only about 1,500 cases are diagnosed each year in
New Treatment for WM Could Soon be Approved in the EU
According to a press release from Business Wire, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recently issued a positive
Second-Ever Therapy for Waldenström’s Macroglobulinemia is Now FDA Approved
The FDA has just announced their approval of zanubrutinib (Brukinsa) as a therapeutic option for Waldenström’s macroglobulinemia. This approval was given based on the ASPEN
